Remaining Need for In Vitro Test to Elucidate 5-Hydroxytryptamine 2C Receptor Functioning

To the Editors:

Serotonin (5-hydroxytryptamine [5-HT]) plays an important role within the nervous system (serotonergic neurons), endocrine system (enterochromaffin cells), immune system (leucocytes), and many other organ systems. The effects of serotonin are mediated by a divergent group of 5-HT receptors, including several subtypes. Research presented in this letter involves genetic variants of the G-protein coupled 5-HT2C receptor, linked to the multifunctional phosphoinositide signalling system primarily activating phosphokinase C. 5-HT2C receptors are widely distributed in the central nervous system and have been implicated in processes regulating mood, cognition, sleep, and extrapyramidal control. The 5-HT2C receptor gene (HTR2C) is chromosome X-linked and contains various single nucleotide polymorphisms (SNPs), for example, rs6318. This missense mutation has indeed been associated with dysfunction of serotonergic neurotransmission in various psychiatric disorders, and in the development of adverse effects of antipsychotic and antidepressant therapy, thus implicating functional consequences. Recently, Fedorenko et al. described a possible protective effect of the 23Cys-HTR2C in antipsychotic-drug-induced hyperprolactinemia. However, in another patient population, an even higher association was found between hyperprolactinemia and the G-HTR2C allele of rs569959. The 5-HT2C receptor is an excitatory receptor displaying constitutive activity in the absence of the neurotransmitter. Accordingly, full blockade of the 5-HT2C receptor decreases its excitatory activity and the activation of the affected cell. This mechanism might also explain why atypical antipsychotics have fewer propensities for Parkinsonism and tardive dyskinesia than classical antipsychotic drugs. It could be argued that the 23Ser-5HT2C variant will differently respond to 5-HT2C antagonists, which might also have consequences for the likelihood of adverse reactions during treatment with atypical antipsychotics. However, recombinant human 23Cys-5HT2C and 23Ser-5HT2C receptors did not differ in their electrophysiological response to 5-HT when expressed in Xenopus oocytes. Also, experiments using COS-7 and HEK293 cell lines revealed no functional difference between these variants. Okada et al. observed higher constitutive activity of 23Ser-5HT2C than 23Cys-5HT2C receptors in S9 cell lines. Recombinant receptors may not adequately reflect the real life differences between genetic variants because the differences may be related to epigenetic variability or the assessed SNP may be in linkage disequilibrium with other genetic variants. Therefore, an ex vivo model to explore the functionality of genuine human 23Cys-5HT2C and 23Ser-5HT2C receptors in normal cells is urgently needed to explain the effects of the Cys23Ser-HTR2C missense mutation or polymorphisms, which are not in linkage disequilibrium with rs6318.

Serotonin also has an important role as immune modulator. The effects may be cell-specific and depend on the expression of serotonergic components in immune cells. Similarities in 5-HT function within nerve and immune cells have led to the suggestion that blood lymphocytes could be used as a convenient probe for a number of neuronal cell functions. Marazzitti et al. demonstrated the presence of specific messenger RNA for 5-HT2C receptors in resting lymphocytes of healthy subjects and patients with obsessive-compulsive disorder and with bipolar disorder. It is thus very well possible that 5-HT2C receptor’s functionality can be assessed by investigating the effects of 5-HT2C receptor agonists on intracellular transduction. To this end, Zhang et al. developed and optimized a cellular inositol monophosphatase 1 assay for the characterization of 5-HT2C receptor ligands using Chinese hamster ovary cells. Our aim was to use a less complicated assay to determine the functionality of 5-HT2C receptors in readily available cells of human patients. We have therefore investigated whether 5-HT2C induced calcium uptake by lymphocytes could be a viable alternative.

The aim of our study was to determine whether intracellular calcium could be measured upon stimulation of the 5-HT2C receptor in human female peripheral mononuclear cells (PBMCs). The methods and obtained results are described in detail in the supplemental material (Supplementary Data, Supplemental Digital Content 1, www.psychopharmacology.com).
HTR2C samples. After the addition of ATP, a clear ionophore digitonin compared with control was obtained after addition of the calcium in freshly isolated PBMCs. A strong signal of a calcium ionophore (ie, digitonin) or di-trial, it was measured whether application http://links.lww.com/JCP/A508). In the first series of experiments, the freshly isolated PBMCs were incubated overnight (17–22 hours), with increasing concentrations of lipopolysaccharide (LPS) (ie, 0 ng/mL, 1 ng/mL, 10 ng/mL, and 100 ng/mL). This did not induce robust differences with respect to the sensitivity to 5-HT2C receptor stimulation (Fig. 1).

Hence, in human PBMCs, we failed to show any effect of 5-HT2C receptor activation on intracellular free calcium levels. Also, LPS-induced monocyte activation failed to affect the sensitivity for 5-HT2C receptor agonists. This failure could be due to accidental inactive 23Ser-5-HT2C receptor homozygosity of the donors. However, because the HTR2C gene is chromosome X-linked, the frequency of the 23Ser allele in healthy Caucasian males was only 0.13 and, because we used PBMCs of different female donors, this is highly unlikely.

In our opinion, it is of the utmost importance to study the activity of 5-HT2C receptors in normal human Cys23Ser HTR2C (rs6318) carriers. It is important to note that the amino acid substitution on position 23 of the 5-HT2C receptor is not necessarily causing a change in activity. The SNP can still be in equilibrium with other genetic variants, and/or the different pharmaceutical activity could be dependent upon the proper biochemical (epigenetic) context within human cells. Clearly, the latter can only be elucidated using suitable material of human carriers. Importantly, such a model could be an important future tool for treatment response prediction in psychiatry. Intracellular calcium release of human PBMCs may not be a viable model, so we urge our colleagues to report their serendipitous findings with other ex vivo models.

AUTHOR DISCLOSURE INFORMATION
The research described in this report was made possible by an unconditional research grant from Servier Pharma Netherlands (NR 12.297 PST). Writing this report has partly been carried out within the framework of Tomsk Polytechnic University Enhancement Program (S.A. Ivanova). The authors declare no conflicts of interest.

Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.psychopharmacology.com).

Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Svetlana A. Ivanova, MD, PhD
Mental Health Research Institute
Tomsk National Research Medical Center
Tomsk, Russian Federation

Melloney J. Dröge, PharmD, PhD
Haukeline H. Volders, BSc
Analytical Biochemical Laboratory
Assen, The Netherlands

Bernard J. van Vliet, PhD
Integrex Research
Groningen, The Netherlands

Nikolay A. Bokhan, MD, PhD
Mental Health Research Institute
Tomsk National Research Medical Center
Tomsk, Russian Federation

Fokko J. Bosker, PhD
University Centre for Psychiatry
University Medical Centre Groningen
University of Groningen
Groningen, The Netherlands

Anton J.M. Loonen, MD, PharmD, PhD
Unit of Pharmacotherapy
Pharmacopelidiology and Pharmacoconomics
Groningen Research Institute of Pharmacy
University of Groningen
Groningen, The Netherlands

REFERENCES
1. Arnaola R, Becerril-Villanueva E, Cruz-Fuentes C, et al. Immunomodulatory effects mediated by serotonin. J Immunol Res. 2015;2015:354957.
2. Pandey SC, Davis JM, Pandey PN. Phosphoinositide system-linked serotonin receptor subtypes and their pharmacological properties and clinical correlates. J Psychiatry Neuosci. 1995;20:215–225.

3. Leysen JE. 5-HT2 receptors. Curr Drug Targets CNS Neurol Disord. 2004;3:11–26.
4. Loonen AJM, Ivanova SA. Role of 5-HT2C receptors in dyskinesia. Int J Pharm Pharm Sci. 2014;8:5–10.
5. Loonen AJ, Ivanova SA. New insights into the mechanism of drug-induced dyskinesia. CNS Spectr. 2013;18:15–20.
6. Lappalainen J, Zhang L, Dean M, et al. Identification, expression, and pharmacology of a Cys23Ser substitution in the human 5-HT2c receptor gene (HTR2C). Genomics. 1995;27:274–279.
7. Drago A, Serretti A. Focus on HTR2C: a possible suggestion for genetic studies of complex disorders. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:601–637.
8. Houston JP, Kohler J, Bishop JK, et al. Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. J Clin Psychiatry. 2012;73:1077–1086.
9. Gunes A, Dahl ML, Spina E, et al. Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. Eur J Clin Pharmacol. 2008;64:477–482.
10. Fedorenko OY, Loonen AJM, Vyalova NM, et al. Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia. Physiol Pharmacol. 2017;21:25–33.
11. Ivanova SA, Osmanova DZ, Freidin MB, et al. Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinemia in antipsychotic drug-treated patients with schizophrenia. World J Biol Psychiatry. 2017;18:239–246.
12. Aloyo VJ, Berg KA, Spampinato U, et al. Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors. Pharmacol Ther. 2009;121:160–173.
13. Fentress HM, Grinde E, Mazurkiewicz JE, et al. Pharmacological properties of the Cys23Ser single nucleotide polymorphism in human 5-HT2C receptor isoforms. Pharmacogenomics J. 2005;5:244–254.
14. Okada M, Nortrup JK, Ozaki N, et al. Modification of human 5-HT(2C) receptor function by Cys23Ser, an abundant, naturally occurring amino-acid substitution. Mol Psychiatry. 2004;9:55–64.
15. Gładkiewicz A, Kauflmann HE, Kor J Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:559–576.
16. Marazziti D, Ori M, Nardini M, et al. mRNA expression of serotonin receptors of type 2C and 5A in human resting lymphocytes. Neuropsychobiology. 2001;43:123–126.
17. Zhang YJ, Kowal DM, Nawoschik SP, et al. Development of an improved IP(1) assay for the characterization of 5-HT(2C) receptor ligands. Assay Drug Dev Technol. 2010;8:106–113.